Spotlight
Clinical Role
Clinical
Supplement Spotlight
CE
Subscribe
Opinion
Video
Key Considerations for Oncology Pharmacists When Selecting and Sequencing ADC Therapies
Panelists discuss how when making antibody-drug conjugate (ADC) treatment decisions for patients with metastatic breast cancer (mBC), pharmacists primarily consider patient-specific factors such as biomarker status, prior therapies, disease burden, and comorbidities. ADCs are typically introduced after standard first-line treatments show inadequacy or in specific molecular subtypes that demonstrate strong responses to targeted therapy.
Video content above has been prompted by the following:
- What key factors guide pharmacists in treatment sequencing decisions when multiple ADCs are available for mBC, and when is ADC therapy typically introduced?
Related Videos
Related Content
